DFDieter Felsenberg

Dieter Felsenberg

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Dieter Felsenberg has a total of 75 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

    • 1 September 2013
      • Vol. 13  (3) , 312-9

    Cross-sectional assessment of neuromuscular function using mechanography in women and men aged 20-85 years.

    by R Dietzel, U Gast, T Heine, D Felsenberg, G Armbrecht

    The aim of this cross-sectional study was to examine the influence of age and sex on neuromuscular function of the lower limbs using mechanography. 704 adults aged 20-85 years from Germany participated in this study. Ground reaction force and power were assessed with countermovement jumps and the chair rising test on a ground reactions force plate. While ground reaction force per unit body mass declined by about 20% from the third to the ninth decade, the decline of power per unit body mass was much greater, varying between 40-50%. Men and women are affected equally by the decline. Age and sex explained the variability of the power parameters to a much greater extent (R(2)=0.54 to R(2)=0.70) than the force parameters (R(2)=0.18 to R(2)=0.36). Our reference values can help to identify those who might be affected by the development of sarcopenia. Preventive exercise programs should focus on preserving muscle power in addition to the training of muscle force.


    • 1 March 2013
      • Vol. 13  (1) , 66-76

    Bone strength and density via pQCT in post-menopausal osteopenic women after 9 months resistive exercise with whole body vibration or proprioceptive exercise.

    by N Stolzenberg, D L Belavý, G Beller, G Armbrecht, J Semler, D Felsenberg

    In order to better understand which training approaches are more effective for preventing bone loss in post-menopausal women with low bone mass, we examined the effect of a nine-month resistive exercise program with either an additional whole body vibration exercise (VIB) or balance training (BAL). 68 post-menopausal women with osteopenia were recruited for the study and were randomised to either the VIB or BAL group. Two training sessions per week were performed. 57 subjects completed the study (VIB n=26; BAL n=31). Peripheral quantitative computed tomography (pQCT) measurements of the tibia, fibula, radius and ulna were performed at baseline and at the end of the intervention period at the epiphysis (4% site) and diaphysis (66% site). Analysis was done on an intent-to-treat approach. Significant increases in bone density and strength were seen at a number of measurement sites after the intervention period. No significant differences were seen in the response of the two groups at the lower-leg. This study provided evidence that a twice weekly resistive exercise program with either additional balance or vibration training could increase bone density at the distal tibia after a nine-month intervention period in post-menopausal women with low bone mass.


  • Osteonecrosis of the jaw in patients with osteoporosis — A remarkable risk of bisphosphonate treatment?

    by D. Felsenberg, B. Hoffmeister, T. Jung, S. Lopez-Schüler, O. Bock


  • Changes of muscle and bone mass and bone marker during simulated weightlessness in exercise and control group— Results from Berlin Bed Rest Study

    by D. Felsenberg, D. Belavy, T. Miocovic, G. Armbrecht, G. Beller, U. Gast, H. Roth, H. Schießl, B. Buehring, F. Dimeo, et al.


  • Impact of alfacalcidol on bone mineral density (pQCT & DXA) of radius, tibia, spine and hip in postmenopausal alendronate treated women with reduced bone mass

    by D. Felsenberg, O. Bock, H. Boerst, G. Armbrecht, G. Beller, C. Degner, E. Schacht, Z. Mazor, J. Hashimoto, P. Martus, et al.

    • 16 July 2008
      • Vol. 8  (2) , 179-87

    Whole body vibration in cystic fibrosis--a pilot study.

    by J Roth, M Wust, R Rawer, D Schnabel, G Armbrecht, G Beller, I Rembitzki, U Wahn, D Felsenberg, D Staab

    In cystic fibrosis (CF), bone mass deficits as well as a lack of muscle mass and force have been described. The bone mass deficits are thought to be at least in part secondary to the reduced muscle mass. Whole body vibration has recently been suggested as an effective technique to increase muscle force and power. The aim of this pilot study was to evaluate the compliance and safety of a side-alternating, whole body vibration platform in patients with CF and to assess its effects on muscle force, muscle power, bone mass and lung function. Eleven adult CF patients participated in a six-months home-based training programme on a whole body vibration platform. Muscle force and power were assessed with three standard manoeuvres on a ground reaction force plate at regular intervals. Bone densitometry was performed at the spine, the radius and the tibia using quantitative computerized tomography. Regular cardiovascular monitoring did not show any critical drop in oxygen saturation or blood pressure. Lung function remained relatively constant with a median FEV1 change [% of norm] of -3.1% (range -7-20). Trabecular density at the spine and parameters of bone density and geometry at the radius and tibia did not show consistent changes. A median decrease of -0.3% (-31.0-17.9) for muscle force and a median increase of 4.7% (-16.4-74.5) for muscle power and 6.6% (-0.9-48.3) for velocity was noted in the two-leg jump. In the one-leg jump, a median increase of 6.7% (-8.5-24.3) for muscle force was measured. Whole body vibration was well tolerated in the majority of the study participants. Most patients were able to increase peak force in the one-leg jump. In the two-leg jump, velocity and muscle power increased with equal or decreased muscle force. This may indicate an improvement in neuromuscular and intramuscular co-ordination (and therefore efficiency) with less muscle force necessary to generate the same power.


    • 14 July 2007
      • Vol. 7  (2) , 144-8

    Common musculoskeletal adverse effects of oral treatment with once weekly alendronate and risedronate in patients with osteoporosis and ways for their prevention.

    by O Bock, H Boerst, F E Thomasius, C Degner, M Stephan-Oelkers, S M Valentine, D Felsenberg

    To examine in a major cohort of patients whether or not musculoskeletal adverse effects (MAEs), similar to those seen in intravenous bisphosphonates (BP), might occur also in high dosage oral treatment regimens with alendronate (ALN) and risedronate (RSN). 612 consecutive patients treated in the osteoporosis outpatient clinic at Charite, Campus Benjamin Franklin, between July 2002 and October 2003 with oral ALN or RSN (mean age 68.2+/-9.7 years; 527 females, 85 males), were examined and followed up for MAEs. The overall frequency of any severe MAEs in our patients was low (5.6%). All severe MAEs occurred in primarily once weekly treated patients: 27 in ALN 70 mg once weekly (27/134=20.1%) and 7 in RSN 35 mg once weekly (7/28=25.0%), with no significant difference between those groups. The most frequently reported MAE was acute arthralgia in 12.6%, followed by acute back pain in 9.1% of all primarily once weekly treated cases. None of the 302 patients initially treated with daily BP reported any MAEs when later switching to once weekly administration (218 patients to ALN 70 mg once weekly and 84 patients to RSN 35 mg once weekly). With reference to recently published data, the phenomenon is probably related to dose dependent gammadelta T cell activation by accumulation of isopentenyl pyrophosphate (IPP) due to inhibition of the mevalonate pathway by nitrogen containing bisphosphonates (nBP). MAEs in oral BP are, in general, less common and severe than in intravenous BP. They are observed exclusively in patients starting ALN or RSN treatment with once weekly dosage regimens. In order to avoid this phenomenon, it is suggested to start ALN or RSN treatment with the lower daily dosages of ALN 10 mg daily or RSN 5 mg daily for about two weeks before switching to the overall, more convenient, once weekly dose regimen.


  • Placebo-controlled multicenter study of oral alendronate in postmenopausal osteoporotic women

    by Dieter Felsenberg, Friederike Alenfeld, Oliver Bock, Christine Hammermeister, Wolfgang Gowan and the FOSIT-Study-Group


  • Bone densitometry: applications in sports-medicine

    by Dieter Felsenberg, Wolfgang Gowin


    • 15 March 1998
      • Vol. 93

    [Morphometric analysis of roentgen images of the spine for diagnosis of osteoporosis-induced fracture].

    by D Felsenberg, E Wieland, W Gowin, G Armbrecht, X Bolze, A Khorassani, U Weingarten